PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2018-04-23
Target enrollment:
Participant gender:
Summary
Phase II open-label single-arm prospective multicentric clinical trial of PF-05212384
(PKI-587) delivered by intravenous route. A 2-stage Fleming design will be employed.